Upadacitinib stops Structural Joint Damage Progression in Rheumatoid Arthritis: Study Dr. Shravani Dali25 Feb 2022 9:00 AM ISTUpadacitinib stops Structural Joint Damage Progression in Rheumatoid Arthritis, according to a recent study published in the Rheumatology. A study...
Upadacitinib Monotherapy Hampers Joint Damage in RA: Study Dr. Shravani Dali19 Feb 2022 9:00 AM ISTUpadacitinib monotherapy is beneficial in inhibiting structural joint damage progression in patients with rheumatoid arthritis, according to a...
High dose Upadacitinib produces added advantage in moderate to severe atopic dermatitis Hina Zahid13 Dec 2021 9:00 AM ISTUpadacinib is a new drug for the treatment of adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis who are...
Compared to Dupilumab Upadacitinib rapidly improves itching and clears skin in atopic dermatitis: JAMA Dr Manoj Kumar Nayak9 Aug 2021 9:00 AM ISTUpadacitinib vs Dupilumab in adult atopic dermatitis (AD) : JAMA studyAtopic dermatitis is a severely pruritic relapsing disorder with multiple...
Upadacitinib effective in patients with psoriatic arthritis and axial involvement: Study Medha Baranwal3 July 2021 9:00 AM ISTDelhi: Upadacitinib (UPA) is effective for the treatment of psoriatic arthritis (PsA) and axial involvement, finds a recent study. Patients with PsA...
Oral upadacitinib an effective treatment option for eczema, study shows Hina Zahid27 May 2021 8:30 AM ISTUSA: Monotherapy with oral medication upadacitinib could be a potential treatment and has a positive benefit-risk profile in people with...
Upadacitinib found effective for psoriatic arthritis patients, Finds Study Dr. Nandita Mohan10 March 2021 8:47 PM ISTAccording to recent research, it has been found out that patients with active PsA who had inadequate response or intolerance to at least one...
CHMP Approves Upadacitinib for Treating Active Psoriatic Arthritis and Ankylosing Spondylitis Hina Zahid14 Dec 2020 12:08 PM ISTNORTH CHICAGO, Ill., - AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use...
Upadacitinib bests abracept in tough Rheumatoid Arthritis Cases: NEJM study Dr. Nandita Mohan22 Oct 2020 10:57 AM ISTUpadacitinib is an oral selective Janus kinase inhibitor to treat rheumatoid arthritis. The efficacy and safety of upadacitinib as compared with...
Upadacitinib Plus topical steroids Improve symptoms in Atopic Dermatitis: Phase 3 Study Hina Zahid3 Aug 2020 6:30 PM ISTNORTH CHICAGO -- AbbVie (NYSE: ABBV) today announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary...
Upadacitinib may alone improve treatment outcomes in rheumatoid Arthritis: Study Dr.Niharika Harsha B31 July 2020 8:57 PM ISTMonotherapy with Upadacitinib demonstrated significant improvements in clinical, radiographic, and patient‐reported outcomes in patients with...
Upadacitinib monotherapy alone may improve RA significantly Dr. Kamal Kant Kohli12 July 2020 6:53 PM ISTResearchers have found in a clinical trial of patients with rheumatoid arthritis that JAK inhibitor upadacitinib may lead to significant improvements...
